Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could cord cell secretions ease arthritis pain?

NCT ID NCT07715045

Disease control Sponsor: Universitas Sriwijaya Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study tests whether a substance produced by umbilical cord cells can help control moderate rheumatoid arthritis. Participants receive weekly injections of either the cell substance or a placebo for six weeks, alongside their usual medication. The goal is to see if it improves symptoms and reduces inflammation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a substance from umbilical cord cells (UC-MSC secretome)
What this could lead to
If it works, this could offer a new way to control rheumatoid arthritis symptoms for people who don't respond well to standard drugs.
What could go wrong
This is a small, early-phase trial, so results may not apply to everyone. The treatment is still experimental and may not work better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

40 people

The number who actually took part.

Started

Feb 2026

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * -Adults aged 18 to 60 years. * Diagnosis of rheumatoid arthritis according to the 2010 ACR/EULAR Classification Criteria. * Moderate disease activity (DAS28-CRP \>3.2 and ≤5.1). * Receiving stable conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy for at least 3 months before enrollment. * Stable dose of corticosteroids and/or NSAIDs for at least 4 weeks before enrollment, if applicable. * Willing and able to provide written informed consent. Exclusion Criteria: * Other autoimmune rheumatic diseases or overlap syndromes. * Active tuberculosis or other severe active infections. * Active hepatitis B, hepatitis C, or HIV infection. * History of malignancy. * Severe renal impairment or severe hepatic dysfunction. * Uncontrolled diabetes mellitus or uncontrolled cardiovascular disease. * Pregnancy or breastfeeding. * Known hypersensitivity to the study intervention or its components. * Participation in another interventional clinical trial within the previous 3 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rheumatoid arthritis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rheumatoid arthritis

Contacts and locations

Locations

  • Dr. Mohammad Hoesin General Hospital

    Palembang, South Sumatera, 30126, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.